Literature DB >> 17699267

Spectrum of renal diseases associated with extreme forms of insulin resistance.

Carla Musso1, Edward Javor, Elaine Cochran, James E Balow, Phillip Gorden.   

Abstract

Diabetic nephropathy is the leading cause of ESRD in the United States. Why the pathogenic mechanisms lead to nephropathy in certain patients with type 1 and 2 diabetes and spare others is unclear, but it is clear that hyperglycemia and glomerular hyperfiltration are important factors. In patients with syndromes of extreme insulin resistance, proteinuric forms of renal disease are common, but it is surprising to find that the renal pathology usually is not diabetic nephropathy. For instance, in the lipodystrophy syndromes, membranoproliferative glomerulonephritis type 1 and type 2, focal segmental glomerulosclerosis, and also diabetic nephropathy are seen. In the syndromes of autoantibodies to the insulin receptor, the various forms of lupus glomerulonephritis are seen. Even in patients with type 2 diabetes, the renal pathology may not be diabetic nephropathy. Therefore, in patients with syndromic forms of insulin resistance and type 2 diabetes, renal biopsy has an important role in defining the pathology that leads to proteinuric nephropathy and in formulating a therapeutic approach. It is the purpose of this article to review these unusual aspects of proteinuric nephropathy in patients with diabetes.

Entities:  

Mesh:

Year:  2006        PMID: 17699267     DOI: 10.2215/CJN.01271005

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  25 in total

Review 1.  Lipodystrophies: adipose tissue disorders with severe metabolic implications.

Authors:  Víctor A Cortés; Marta Fernández-Galilea
Journal:  J Physiol Biochem       Date:  2015-04-02       Impact factor: 4.158

Review 2.  The long-term renal and cardiovascular consequences of prematurity.

Authors:  Carolyn L Abitbol; Maria M Rodriguez
Journal:  Nat Rev Nephrol       Date:  2012-02-28       Impact factor: 28.314

Review 3.  The good, the bad, and the ugly facets of insulin resistance.

Authors:  K V S Hari Kumar
Journal:  Med J Armed Forces India       Date:  2020-01-06

Review 4.  Metreleptin for injection to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.

Authors:  Cristina Adelia Meehan; Elaine Cochran; Andrea Kassai; Rebecca J Brown; Phillip Gorden
Journal:  Expert Rev Clin Pharmacol       Date:  2015-10-14       Impact factor: 5.045

Review 5.  Sodium Glucose Cotransporter-2 Inhibition in Heart Failure: Potential Mechanisms, Clinical Applications, and Summary of Clinical Trials.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Jacob A Udell; Julie A Lovshin; David Z I Cherney
Journal:  Circulation       Date:  2017-10-24       Impact factor: 29.690

6.  Effects of metreleptin on proteinuria in patients with lipodystrophy.

Authors:  Ho Lim Lee; Meryl A Waldman; Sungyoung Auh; James E Balow; Elaine K Cochran; Phillip Gorden; Rebecca J Brown
Journal:  J Clin Endocrinol Metab       Date:  2019-04-16       Impact factor: 5.958

7.  Renal complications of lipodystrophy: A closer look at the natural history of kidney disease.

Authors:  Baris Akinci; Sadiye Mehtat Unlu; Ali Celik; Ilgin Yildirim Simsir; Sait Sen; Banu Nur; Fatma Ela Keskin; Basak Ozgen Saydam; Nilufer Kutbay Ozdemir; Banu Sarer Yurekli; Bekir Ugur Ergur; Melda Sonmez; Tahir Atik; Atakan Arslan; Tevfik Demir; Canan Altay; Ulku Aybuke Tunc; Tugba Arkan; Ramazan Gen; Erdal Eren; Gulcin Akinci; Aslihan Arasli Yilmaz; Habib Bilen; Samim Ozen; Aygul Celtik; Senay Savas Erdeve; Semra Cetinkaya; Huseyin Onay; Sulen Sarioglu; Elif Arioglu Oral
Journal:  Clin Endocrinol (Oxf)       Date:  2018-05-17       Impact factor: 3.478

8.  A case of Dunnigan-type familial partial lipodystrophy (FPLD) due to lamin A/C (LMNA) mutations complicated by end-stage renal disease.

Authors:  Hitomi Imachi; Koji Murao; Shouji Ohtsuka; Mako Fujiwara; Tomie Muraoka; Hitoshi Hosokawa; Toshihiko Ishida
Journal:  Endocrine       Date:  2008-11-15       Impact factor: 3.633

Review 9.  Role of altered insulin signaling pathways in the pathogenesis of podocyte malfunction and microalbuminuria.

Authors:  Alexandra Jauregui; Daniel H Mintz; Peter Mundel; Alessia Fornoni
Journal:  Curr Opin Nephrol Hypertens       Date:  2009-11       Impact factor: 2.894

10.  Efficacy of leptin therapy in the different forms of human lipodystrophy.

Authors:  A Y Chong; B C Lupsa; E K Cochran; P Gorden
Journal:  Diabetologia       Date:  2009-09-02       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.